News & Events

Press Releases

February 26 2021

vasopharm Appoints Chief Medical Officer

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Prof Dr John F. Stover as Chief Medical Officer.

Read on Download PDF
July 11 2019

vasopharm Closes € 9.5 million Financing Round

vasopharm today announced the successful completion of a € 9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments. Existing investors Bayern Kapital, Future Capital, clients of Hanseatic Asset Management and Ringtons Holdings also participated in the round. In addition, vasopharm welcomed Creathor Ventures as new investor and Christian Leikert, Partner at Creathor Ventures, joins vasopharm’s board of directors.

Read on Download PDF
March 15 2018

Vasopharm Provides Update on Phase III Traumatic Brain Injury Trial

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH, a privately held biopharmaceutical company, today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial. This milestone triggers an interim review by the Data Monitoring Committee (DMC) in line with the agreed study protocol. Allowing for the six month extended Glasgow Outcome Scale (eGOS) evaluation for the 110th eligible patient recruited, the company expect feedback from the DMC in Q4 2018.

Read on Download PDF
November 8 2016

vasopharm appoints Chief Medical Officer

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer. In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.

Read on Download PDF